XD14
Code | Size | Price |
---|
SYN-3048-M100 | 100 mg | Enquire |
Quantity:
SYN-3048-M001 | 1 mg | £92.00 |
Quantity:
SYN-3048-M005 | 5 mg | £151.00 |
Quantity:
SYN-3048-M010 | 10 mg | £244.00 |
Quantity:
SYN-3048-M050 | 50 mg | £771.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Storage:
+4°C
Images
Documents
Further Information
Alternate Names/Synonyms:
4-Acetyl-N-[5-[(diethylamino)sulfonyl]-2-hydroxyphenyl]-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide
Appearance:
Solid.
CAS:
1370888-71-3
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C20H27N3O5S/c1-6-15-18(13(5)24)12(4)21-19(15)20(26)22-16-11-14(9-10-17(16)25)29(27,28)23(7-2)8-3/h9-11,21,25H,6-8H2,1-5H3,(H,22,26)
InChiKey:
DPBKLIVPNYGQQG-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1370888-71-3. Formula: C20H27N3O5S. MW: 421.5. BET bromodomain inhibitor with Kd values of 160, 170, 380, 490, 830 and 850nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively. XD14 also inhibits BRDT(1), CBP, p300 and BRDT(2) with Kd values of 1.2, 1.6, 2.6 and 3.7µM, respectively. XD14 has shown to attenuate proliferation of HL-60 leukemia cells in vitro.
Molecular Formula:
C20H27N3O5S
Molecular Weight:
421.5
Package Type:
Plastic Vial
Product Description:
BET bromodomain inhibitor with Kd values of 160, 170, 380, 490, 830 and 850nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively. XD14 also inhibits BRDT(1), CBP, p300 and BRDT(2) with Kd values of 1.2, 1.6, 2.6 and 3.7µM, respectively. XD14 has shown to attenuate proliferation of HL-60 leukemia cells in vitro.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
4-Acyl pyrroles: mimicking acetylated lysines in histone code reading: X. Lucas, et al.; Angew. Chem. Int. Ed. Engl. 52, 14055 (2013)
Related Products
Product Name | Product Code | Supplier | LY-294002 | AG-CR1-0108 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|